Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glargine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Standard insulin drip therapy | NO_INTERVENTION | Standard insulin drip therapy |
| Insulin drip and glargine | ACTIVE_COMPARATOR | Insulin drip and glargine 0.25 units per kg body weight |
| Name | Type | Description |
|---|---|---|
| Glargine | DRUG | Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy |
Inclusion Criteria: * Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar non-ketotic states, hyperglycemia with severe illness, pre- and postoperative states, nothing by mouth (NPO), as well as gastric (tube feeding) and parenteral nutrition requiring insulin drip. * Patients with type 1 an...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
Glargine is an investigational small molecule being developed for the treatment of diabetes. It is a long-acting form of insulin designed to be added to insulin drip therapy. The drug is currently in Phase 1 clinical development and has not yet been approved by regulatory authorities.
Glargine is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of Glargine in patients with diabetes.
Glargine is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical trials to assess its safety and effectiveness in treating diabetes.
Glargine has been studied in one completed clinical trial, identified as NCT01153100. This Phase 1 trial enrolled 60 participants with diabetes in the United States and evaluated the effectiveness of adding subcutaneous long-acting Glargine to insulin drip therapy compared with standard insulin drip therapy.
Glargine is a long-acting insulin formulation being developed by Sanofi. It is designed to provide a sustained release of insulin to help manage blood sugar levels in people with diabetes. The drug is currently in Phase 1 clinical trials and is not yet approved for commercial use.